Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

A Vaccine For Ear Infections - Without The Needle
Even when she"s well, little Cammy Barber doesn"t like getting her ears
generic viagra online
Protect Children From The Allure Of Smoking, Say Doctors
BMA Scotland has warned that children who smoke face years of tobacco addiction that can lead to life-threatening diseases and premature death. The association also called on MSPs to support the proposals contained in the Tobacco and Primary Medical services (Scotland) Bill in order to reduce children"s exposure to tobacco products.
News of the day
As They Debate Health Overhaul, Politicians Keep Eye On 2010
"Fifteen months before the midterm congressional election, health care is appearing in candidate stump speeches and interviews - particularly by Republican challengerṣ€¦ running in districts recently claimed by Democrats," USA Today reports. "That dynamic helps explain why a $1 trillion-plus health care bill stalled last week in Congress. ̣€¦ Obama has said he wants lawmakers to finish health care by the end of the year, in part because it could become mired in election-year politics. All 435 members of the House and 36 members of the Senate are up for election in 2010."
Cardiovascular

Eiger BioPharmaceuticals Acquires Exclusive License To Novel Hepatitis C Virus (HCV) Technology From Stanford University

Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that it has licensed the exclusive worldwide rights to novel Hepatitis C Virus (HCV) technology from Stanford University. This technology, discovered in the lab of Stanford scientist and Eiger founder Dr. Jeffrey Glenn, M.D., Ph.D., is focused on a variety of novel targets, including key features of NS4B, a non-structural protein in the HCV genome, which binds to HCV-RNA and is required for viral replication. "We are delighted to have licensed the rights to this exciting new technology from Stanford University," said David Cory, President and CEO of Eiger. "Disrupting the interaction between NS4B and HCV-RNA may be a promising new method to treat HCV infection and help combat drug resistance to HCV polymerase and protease inhibitors. We are rapidly advancing novel small molecule inhibitors of NS4B-RNA binding into the clinic for the benefit of clinicians and HCV patients." "The unique two component nature of the NS4B-RNA target appears to decrease the virus" ability to escape inhibition by the small molecule inhibitors in development at Eiger, and that should decrease HCV resistance to this type of antiviral therapy," said Jeffrey Glenn. "These virus specific agents in development at Eiger possess the promise of more effective, oral drugs that can be essential components of all future cocktails for HCV therapy." About Hepatitis C Virus Infections from HCV have reached pandemic proportions, affecting over 150 million people worldwide. According to the Centers for Disease Control (CDC), 3.9 million Americans have been exposed to HCV, resulting in 2.7 million cases of chronic infection. Chronic HCV infection leads to serious liver disease (e.g. liver scarring and cirrhosis) and is the leading cause of liver cancer and liver transplantation in the U.S. About Eiger BioPharmaceuticals, Inc. Eiger is a biopharmaceutical company focused on the discovery and development of new antiviral agents against novel targets for the treatment of hepatitis virus infections. Eiger"s pipeline includes repurposed clinical stage therapeutic agents as well as preclinical NCEs from discovery that exhibit antiviral activity against Hepatitis C, Hepatitis D, and other viruses. Eiger BioPharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009